Kiniksa Pharmaceuticals International, plc

Good day, and thank you for standing by, and welcome to Kineska Pharmaceuticals first quarter 2024 earnings conference call. At this time, all participants are in the listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Rachel Frank, head of investor relations. Please go ahead.

Thank you, operator. Good morning, everyone, and thank you for joining Connexus Call to discuss our first quarter 2024 financial results in recent portfolio execution. A press release highlighting these results can be found on our website under the investor section. As for the agenda, our chief executive officer, Sanj K. Patel, will start with an introduction. Ross Moat, our Chief Commercial Officer, will provide an update on our ARCLS commercial execution. John Paolini, our Chief Medical Officer, will provide an Abby Prubart program review. And Mark Ragosa, our Chief Financial Officer, will review our first quarter 2024 financial results. And finally, John will return for closing remarks and to kick off the Q&A session for which Evan Tesari, our Chief Operating Officer, will also be on the line. Before getting started, please note that we will be making forward-looking statements today that are subject to risks and uncertainties that may cause actual results to differ materially from these statements. A review of such statements and risk factors can be found on this slide, as well as under the caption, Risk Factors, contained in our SEC filing. These statements speak only as of the date of this presentation, and we undertake no obligation to update such statements except as required by law. With that, I will turn it over to Sanj.

Thanks, Rachel, and good morning, everyone. We are very encouraged with the ARCLIS commercial progress. We continued to build upon the ARCLIS performance this quarter, marked by reaching an increasing number of recurrent pericarditis patients and growing to a net product revenue of $78.9 million. We continue to see strength across key commercial drivers, including growing prescriber adoption, and high physician and patient satisfaction, which has been supported by our focus on frequent engagement with the existing and potential prescribers. Importantly, we're also seeing an expanding utilization of Arclist as a steroid-sparing therapy for patients suffering from recurrent pericarditis. Looking to the year ahead, we now expect Arclist full-year sales to be between $370 million to $390 million. And this would represent 63% year-over-year growth at the midpoint. In terms of our pipeline, we recently announced plans to initiate a Phase IIb trial with Aviprobar in Sjogren's disease. This is a debilitating disorder with no current FDA-approved therapies. And we believe Aviprobar has the potential to provide meaningful benefit to patients. Dr. John Paolini, our Chief Medical Officer, will provide additional details about our planned Phase 2b trial, which is expected to initiate in the second half of this year. And with that, I'll now turn it over to Ross to review our commercial execution.